Gene · 5687
PSMA6: proteasome 20S subunit alpha 6
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMA6: proteasome 20S subunit alpha 6. Genes, record 5687. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5687
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P60900 | Proteasome subunit alpha type-6 | 246 | 176 | Ensembl, GeneID, HGNC |
Source UniProt
Patents37
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59516 | P60900 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1900 | P60900 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1900 | P60900 | Espacenet |
| JP 2024009871 A | 2024-01-23 | 82 | P60900 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67878 | P60900 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170849 | P60900 | Espacenet |
| JP 2021521876 A | 2021-08-30 | 96 | P60900 | Espacenet |
| WO 2019211343 A1 | 2019-11-07 | 82 | P60900 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 239951 | P60900 | Espacenet |
| EP 3403091 A1 | 2018-11-21 | 685 | P60900 | Espacenet |
1 to 10 of 37
See all 37 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants610
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMA6 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 4 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 2 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 2 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 2 | 2025 |
1 to 10 of 610Source NIH's project files
See all 610 nih grantsPapers729
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PSMA6 drives non-small cell lung cancer progression by stabilizing NEDD8 and activating NF-κB signaling. | Transl Lung Cancer Res | 2026 | 42723894 | PubTator, text mining | PubMed |
| Identification of PANoptosis-related biomarkers in spinal cord injury (SCI) through multi-omics analysis and machine learning. | Int J Neurosci | 2026 | 42037113 | PubTator, text mining | PubMed |
| Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation. | Int J Med Sci | 2026 | 41799753 | PubTator, text mining | PubMed |
| Identification of causally linked blood biomarkers for Alzheimer's disease via reverse transcriptome-wide Mendelian randomization. | J Alzheimers Dis | 2026 | 41789865 | PubTator, text mining | PubMed |
| A new digenic inheritance of proteasome-associated autoinflammatory syndrome involving the PSMA6 gene. | J Allergy Clin Immunol Pract | 2026 | 41205671 | PubTator, text mining | PubMed |
| Zinc-Related Proteasome Variants in Type 1 Diabetes: An in Silico-Guided Case-Control Study. | Metabolites | 2025 | 41441015 | PubTator, text mining | PubMed |
| Enhanced microbiological evaluation of brain abscesses by proteomics-based techniques: a prospective cohort study. | Neurosurg Focus | 2025 | 41175401 | PubTator, text mining | PubMed |
| Reverse control of biological networks to restore phenotype landscapes. | Sci Adv | 2025 | 40845098 | PubTator, text mining | PubMed |
| Target discovery-directed pharmacological mechanism elucidation of bioactive natural products. | Med Rev (2021) | 2025 | 40838108 | PubTator, text mining | PubMed |
| Comparative Analysis of the Tumour Mutational Burden in Erosive and Reticular Oral Lichen Planus. | Oral Dis | 2025 | 40616231 | PubTator, text mining | PubMed |
1 to 10 of 729
See all 729 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5687
GET https://conductscience.org/api/genes/v1/5687/patents?page=2